Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Recorded changes
82,180 on record
Recorded policy changes, newest first| Recorded | Payer | Policy | Change |
|---|
| Sep 30, 2026 | Capital Blue Cross | Noninvasive Fetal RHD Genotyping Using Cell-Free Fetal DNA (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.261 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Noncontraceptive Use of Intrauterine Devices (IUDs)PayerPolicy · CAPBLUE-MP-7.026 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Next-Generation Sequencing For The Assessment of Measurable Residual Disease (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.379 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | NeurofeedbackPayerPolicy · CAPBLUE-MP-2.029 | New policy |
|---|
| Sep 30, 2026 | Capital Blue Cross | Neural TherapyPayerPolicy · CAPBLUE-MP-8.012 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Negative Pressure Wound Therapy in the Outpatient SettingPayerPolicy · CAPBLUE-MP-4.004 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Multimarker Serum Testing Related to Ovarian Cancer (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.270 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Multicancer Early Detection Testing (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.387 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Molecular Testing in the Management of Pulmonary Nodules (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.375 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Molecular Testing for The Management of Pancreatic Cysts and Solid Pancreaticobiliary Lesions (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.266 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Molecular Panel Testing of Cancers to Identify Targeted Therapies (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.259 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Molecular Markers in Fine Needle Aspirates of the Thyroid (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.275 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Microwave Tumor AblationPayerPolicy · CAPBLUE-MP-2.090 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Manual Wheelchairs and AccessoriesPayerPolicy · CAPBLUE-MP-6.059 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Lysis of Epidural AdhesionsPayerPolicy · CAPBLUE-MP-6.027 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Low Intensity Pulsed Ultrasound Fracture Healing DevicePayerPolicy · CAPBLUE-MP-6.021 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Liver Transplant and Combined Liver-Kidney TransplantPayerPolicy · CAPBLUE-MP-9.006 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Laser Treatment for Vulvovaginal Atrophy and Vaginal RejuvenationPayerPolicy · CAPBLUE-MP-4.047 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Laparoscopic, Percutaneous, and Transcervical Techniques for Uterine Fibroid MyolysisPayerPolicy · CAPBLUE-MP-7.027 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Laboratory and Genetic Testing for Use of 5-Flourouracil in Patients with Cancer (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.354 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Knee BracesPayerPolicy · CAPBLUE-MP-6.012 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Kidney Transplants, Pancreas Transplants, and Simultaneous Kidney/Pancreas TransplantPayerPolicy · CAPBLUE-MP-9.005 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | KIF6 Genotyping for Predicting Cardiovascular Risk and/or Effectiveness of Statin Therapy (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.309 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Keratoprosthesis and Corneal Surgery (Formerly Corneal Surgery)PayerPolicy · CAPBLUE-MP-9.011 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | JAK2, MPL, and CLR Mutation Analysis in Myeloproliferative Neoplasms (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.281 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Isolated Small Bowel Transplant and Small Bowel/Liver and Multivisceral TransplantPayerPolicy · CAPBLUE-MP-9.013 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Irreversible Electroporation of Tumors Located in the Liver, Pancreas, Kidney or LungPayerPolicy · CAPBLUE-MP-1.162 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Investigational Physical Medicine And Specialized Physical Medicine Interventions (Outpatient)PayerPolicy · CAPBLUE-MP-8.001 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Investigational Miscellaneous Genetic and Molecular Tests (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.277 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Invasive Prenatal (Fetal) Diagnostic Testing (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.278 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Intravenous Chelation TherapyPayerPolicy · CAPBLUE-MP-4.005 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Intraosseous Basivertebral Nerve AblationPayerPolicy · CAPBLUE-MP-1.124 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Intensive Pediatric Feeding ProgramsPayerPolicy · CAPBLUE-MP-2.079 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Implantation of Intrastromal Corneal Ring Segments (Retired 9/1/2026)PayerPolicy · CAPBLUE-MP-1.044 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Hematopoietic Cell Transplantation in the Treatment of Germ-Cell TumorsPayerPolicy · CAPBLUE-MP-9.052 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Hematopoietic Cell Transplantation for Solid Tumors of ChildhoodPayerPolicy · CAPBLUE-MP-9.054 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Hematopoietic Cell Transplantation for Plasma Cell Dyscrasias, Including Multiple Myeloma and POEMS SyndromePayerPolicy · CAPBLUE-MP-9.044 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Hematopoietic Cell Transplantation for Non-Hodgkin LymphomasPayerPolicy · CAPBLUE-MP-9.042 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Hematopoietic Cell Transplantation for Hodgkin LymphomaPayerPolicy · CAPBLUE-MP-9.043 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Hematopoietic Cell Transplantation for Chronic Myeloid LeukemiaPayerPolicy · CAPBLUE-MP-9.039 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaPayerPolicy · CAPBLUE-MP-9.038 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Hematopoietic Cell Transplantation for Autoimmune DiseasesPayerPolicy · CAPBLUE-MP-9.053 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Hematopoietic Cell Transplantation for Acute Lymphoblastic LeukemiaPayerPolicy · CAPBLUE-MP-9.041 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Heart/Lung TransplantPayerPolicy · CAPBLUE-MP-9.014 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Handheld Radiofrequency Spectroscopy for Intraoperative Assessment of Surgical Margins During Breast Conserving SurgeryPayerPolicy · CAPBLUE-MP-5.055 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Germline Genetic Testing for Pancreatic Cancer Susceptibility Genes (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.392 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Germline Genetic Testing for Hereditary Diffuse Gastric Cancer (CDH1,CTNNA1) (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.384 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Germline Genetic Testing for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers (BRCA1, BRCA2, PALB2) (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.211 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Germline And Somatic Biomarker Testing (Including Liquid Biopsy) For Targeted Treatment In Prostate Cancer (Brca1/2, Homologous Recombination Repair Gene Alterations, Ntrk Gene Fusion) (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.394 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Germline And Somatic Biomarker Testing (Including Liquid Biopsy) For Targeted Treatment In Ovarian Cancer (Brca1, Brca2, Homologous Recombination Deficiency, Ntrk) (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.395 | Metadata changed |
|---|